Recent Finacing
Recent Raise
EpiVario is a preclinical drug discovery and development company developing ACSS2-targeting epigenetic modulators administered alongside psychotherapy to prevent pathological memory formation and reconsolidation in PTSD, addiction, and Alzheimer's.